

**Incentives for Change: Addressing the Challenges in Antibacterial Drug Development**

The Brookings Institution • Washington, DC

Wednesday, February 27, 2013

**Participant List**

**James Anderson**

External Partnerships Director,  
Government Affairs, Public Policy and Patient  
Advocacy, GlaxoSmithKline

**David Brumley**

Senior Medical Director, Tufts Health Plan

**Daniel Burgess**

President and Chief Executive Officer, Rempex  
Pharmaceuticals, Inc.

**Angela M. Caliendo**

Executive Vice Chair, Department of Medicine,  
Alpert Medical School of Brown University

**Jeffrey Chodakewitz**

Senior Vice President, Global Scientific Strategy,  
Franchise Head, Infectious Disease and  
Franchise Head (interim) Respiratory &  
Immunology, Merck & Co., Inc.

**Heather Colvin**

Senior Research Associate, Engelberg Center for  
Health Care Reform, The Brookings Institution

**Allan Coukell**

Director of Medical Programs, The Pew  
Charitable Trusts

**Ed Cox**

Director, Office of Antimicrobial Products,  
Center for Drug Evaluation and Research,  
U.S. Food and Drug Administration

**Gregory Daniel**

Managing Director and Fellow, Engelberg Center  
for Health Care Reform, The Brookings Institution

**Mike Dudley**

Senior Vice President, Research & Development,  
and Chief Scientific Officer, Rempex  
Pharmaceuticals, Inc.

**Erin Duffy**

Chief Scientific Officer, Rib-X Pharmaceuticals,  
Inc.

**Michael Dunne**

Chief Medical Officer, Durata Therapeutics

**Barry Eisenstein**

Senior Vice President of Scientific Affairs, Cubist  
Pharmaceuticals and Clinical Professor of  
Medicine, Harvard Medical School

**John Farley**

Deputy Director, Office of Antimicrobial Products,  
Center for Drug Evaluation and Research, U.S.  
Food and Drug Administration

**Calvin Franz**

Senior Economist, Eastern Research Group, Inc.

**Mark Goldberger**

Divisional Vice President, Regulatory Policy and  
Intelligence, AbbVie

**James Gray**

Director of Pharmacy, Barnes-Jewish Hospital

**Robert Guidos**

Vice President, Public Policy and Government  
Relations, Infectious Diseases Society of America

**Aidan Hollis**

Professor of Economics, University of Calgary  
and Vice President, Incentives for Global Health

**Dmitri Iarikov**

Medical Officer, Division of Anti-Infective  
Products, Center for Drug Evaluation and  
Research, U.S. Food and Drug Administration

**John Jenkins**

Director, Office of New Drugs, Center for Drug  
Evaluation and Research, U.S. Food and Drug  
Administration

**Amber Jessup**

Senior Economist, Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services

**Larry Kocot**

Deputy Director, Engelberg Center for Health Care Reform, The Brookings Institution

**Michael Kurilla**

Director of the Office of Biodefense Research Affairs and Associate Director for Biodefense Product Development, National Institute of Allergy and Infectious Diseases

**Katie Laessig**

Deputy Director, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Ben Lorenz**

Medical Officer, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Nicole Mahoney**

Senior Officer, Antibiotics and Innovation Project, The Pew Charitable Trusts

**Mark McClellan**

Director, Engelberg Center for Health Care Reform, Senior Fellow, Economic Studies, and Leonard D. Schaeffer Chair in Health Policy Studies, The Brookings Institution

**Bob Meyer**

Director, Virginia Center for Translational and Regulatory Sciences, University of Virginia School of Medicine

**Brian Murphy**

Pharmacy Director & Reimbursement Consultant, Blue Cross & Blue Shield of Vermont

**Sumathi Nambiar**

Deputy Director for Safety, Division of Anti-Infective Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Thomas S. Neubig**

National Director, Quantitative Economics and Statistics, Ernst & Young LLP

**Kevin Outterson**

Associate Professor, Boston University School of Law

**Richard Platt**

Professor and Chair, Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute

**Dennis Podlesak**

Partner, Domain Associates

**Scott Pope**

Executive Director, Healthcare Innovators Collaborative, Premier, Inc.

**Charlene Reed**

Founder and Chief Executive Officer, Foundation to Combat Antimicrobial Resistance

**John Rex**

Infection Clinical Vice President, AstraZeneca Pharmaceuticals and Adjunct Professor of Medicine, University of Texas Medical School at Houston

**Melissa Robb**

Associate Director for Regulatory Affairs, Office of Medical Policy Initiatives, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Leonard Sacks**

Associate Director for Clinical Methodology, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Jonas Santiago**

Analyst, Division of Medical Policy Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

**Aylin Sertkaya**

Vice President, Eastern Research Group, Inc.

**David Shlaes**

Sole Proprietor and President, Anti-Infectives Consulting

**Anthony D. So**

Professor of the Practice of Public Policy and Global Health, Sanford School of Public Policy, Duke University

**Steve Solomon**

Director, Office of Antimicrobial Resistance, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention

**Brad Spellberg**

Associate Professor of Medicine, Division of  
General Internal Medicine, Los Angeles  
Biomedical Research Institute at Harbor-UCLA  
Medical Center

**Joe Toerner**

Associate Director for Medical Affairs, Office of  
Antimicrobial Products, Center for Drug  
Evaluation and Research, U.S. Food and Drug  
Administration

**John Tomayko**

Senior Medical Director, GlaxoSmithKline

**Nicole Vitullo**

Partner, Domain Associates